Compare · PCSA vs SBFM
PCSA vs SBFM
Side-by-side comparison of Processa Pharmaceuticals Inc. (PCSA) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PCSA and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PCSA is the larger of the two at $5.2M, about 2.3x SBFM ($2.2M).
- PCSA has been more active in the news (10 items in the past 4 weeks vs 5 for SBFM).
- PCSA has more recent analyst coverage (3 ratings vs 0 for SBFM).
- Company
- Processa Pharmaceuticals Inc.
- Sunshine Biopharma Inc.
- Price
- -
- -
- Market cap
- $5.2M
- $2.2M
- 1M return
- +4.48%
- -
- 1Y return
- -74.50%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 3
- 0
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Sunshine Biopharma Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest PCSA
- SEC Form 10-Q filed by Processa Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.
- Processa Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Processa Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Processa Pharmaceuticals Announces Key Leadership Appointments
- SEC Form 8-K filed by Processa Pharmaceuticals Inc.
- Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
- SEC Form EFFECT filed by Processa Pharmaceuticals Inc.
Latest SBFM
- SEC Form DEFA14A filed by Sunshine Biopharma Inc.
- SEC Form 10-Q filed by Sunshine Biopharma Inc.
- SEC Form DEF 14A filed by Sunshine Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.
- SEC Form DEF 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
- SEC Form PRE 14C filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 424B4 filed by Sunshine Biopharma Inc.